Breakfast Presentation Jan 26 2010

8/14/2019 Breakfast Presentation Jan 26 2010

1/23

Sofinnova Capital VI 2010 TrendsJanuary 26, 2010


2/23

Agenda

Welcome

Where we are today:

2009 activity and Sofinnova Capital VI

Breakfast Presentation: January 26, 2010

Confidential

2

Where weve been:a review of investment activity since 1989

Where we are going:

2010 trends

Q&A


3/23


4/23

Sofinnova Partners

Denis Lucquin, Managing Partner (LS)

Antoine Papiernik, Managing Partner (LS)

Monique Saulnier, Managing Partner & CFO


Confidential

4

Jean Schmitt, Managing Partner (IT)

Jean-Bernard Schmidt, Managing Partner

Graziano Seghezzi, Partner (LS)

Olivier Sichel, Partner (IT)

Rafale Tordjman, Partner (LS)


5/23

WHERE WE ARE TODAY

2009 AND SOFINNOVA CAPITAL VI


6/23

We foresee strong M&A activity in 2009for our portfolio companies:

technologies making a real differencefor patients or for customers will alwaysb valuabl such i th beaut of


Confidential

venture. This proves the non-correlationof venture to the rest of the economy.

Denis Lucquin,Managing Partner and Chairman

March 24, 2009

6


7/23

Page 7Sofinnova Portfolio DevelopmentsDeal Activity and Exits of 2009

Feb 09 (SK IV):Sofinnova ofCorevalve (EV 700m$ + milestone

payments)

Feb 09 (SK V): Esmertec mergeswith Purple Labs forming Myriad,Europes largest mobile phone

software company.

Dec 09 (SK V):Movetis to IPO 3years after investment. Sofinnova is

largest shareholder and founding

investor.

Sept 09 (SK IV):Sofinnova Exit ofFovea (EV 370m incl. milestone

payments)

Q1 10:IT Company sold

Value Creation

MERGER

Dec 09 (SK IV):Sofinnova Exit ofNovexel (total cash considerationof $505 million, including earn out

payments of $75 million)

Company X

Jan Aug SepFeb Mar Apr JulMay Oct Nov Dec

Capital Deployed

Jun

June 09 (SK VI):Sofinnova VI invests2.88min DNP Green Technology

June 09 (SK VI):Sofinnova VI invests6.16min CoAxia

June 09 (SK VI):Sofinnova VI invests4.70min Flexion Therapeutics

Q1

2010

Aug 09 (SK VI):Sofinnova VI invests2.8m in MD Start

Aug 09 (SK VI):Sofinnovainvests 3.6 m in Crescendo Nov 09 (SK VI):Sofinnova

VI invests1.50min Celsius

OmtheraPharmaceuticals

Dec 09 (SK VI):SofinnovaVI invests1.4min Omthera


8/23

Sofinnova Capital VI

Closed December 31, 2009

260 million ($370 million) Target was 300 million

Already committed to date: 40% to 50% in ten companies


Confidential

LPs include: CDC Entreprises within the France Investmentprogram, Industrial & Financial Investments Co., JP Morgan

Asset Management, funds advised by Partners Group and

Skandia Life Insurance Company

Sofinnova Partners continues to be recognized by its investors

for its solid investment style and capacity to generate strong

returns, even during turbulent economic times.

8


9/23

WHERE WEVE BEEN

INVESTMENT ACTIVITY SINCE 1989


10/23

Sofinnova Partners:Solid Investment Style

Early-stage, spin offs and restarts are the area of investmentfocus

IP rich technologies


Confidential

Biopharmaceuticals, medical devices, green chemicals,wireless, mobile internet

Europe & USA

Repeat entrepreneurs and experienced management

No me too investments

10


11/23

WHERE WE ARE GOING

2010 TRENDS


12/23

What Does Sofinnova PartnersSuccess Mean for The VC Industry in

Europe? Alive and kicking!

M&A will continue to feed corporate growth


Confidential

IPO window is reopening

Early-stage investment strategy works

Consistent investment in innovation transcends economic

fluctuations

Back to basics: invest only in exceptional companies

12


13/23

2010 Trends: Mobile InternetTHE NEXT GENERATION OF INTERNET, MAY BE EVEN MORE POWERFUL THAN FIXED INTERNET

With new ways to search:


Confidential

New advertising model:

And key software browsers/multimedia:13

Blyk


14/23

2010 Trends: The Mobile Backhaul Issue

MOBILE NETWORKS ARE ABOUT TO MOVE TO FULL IP


Confidential

Needs network intelligence:

And policy management:14


15/23

2010 Trends: The New Digital Frontier

DIGITALIZATION WILL BRING NEW INNOVATIONS

Choosing your home in 3D:


Confidential

Working together:

Listening to music:

15


16/23

2010 Trends: The New User Interface

Everything becoming more tactile:


Confidential

Bringing Convenience and Security:

Bringing security:

16


17/23

2010 Trends: Convergence of Brandsand Technology

PIONEERED BY EUROPEAN INNOVATION

New brands with radical innovations and vision:


Confidential

And a place where design counts:

17


18/23

0

5

10

15

20

25

30

35

2010 Trends: VaccinesGrowthGrowth Old technologyOld technology

[E]

Copyright 2006 Sofinnova Partners

Future InnovationFuture Innovation

0.0

5.0

10.0

15.0

20.025.0

30.0

Birthsperyear(

m)

2008 2018

Seven major markets BRIC countries

BRIC: Brazil, Russia, India, China

$BINFECTIOUS DISEASE

Bacterial

Viral

PROPHYLACTIC VACCINES

SHIFT

CHRONIC DISEASE

Cancer

Diabetes

Alzheimers Disease

THERAPEUTIC VACCINES

18


19/23

GrowthGrowth

$B

0

10

20

30

40

50

60

70

0

50

100

150

200

250

300

350

400

450

2002 2003 2004 2005 2006 2007 2008 2009 2012 2014

2010 Trends: Antibodies

Murine Chimeric Fully HumanHumanizedMurine Chimeric Fully HumanHumanized

30-35

60-65

5-10

90-95 100

100Murine %

Human %

Murine Chimeric Fully HumanHumanizedMurine Chimeric Fully HumanHumanized

30-35

60-65

5-10

90-95 100

100Murine %

Human %

Past InnovationPast Innovation

[E]

[E]

NCE MAB

Copyright 2006 Sofinnova Partners

Full-size antibody

Single-chainantibody (SCA)

Variable region ofLight chain (Vl)

Constant region of

Light chain (Cl) Antigen-bindingFragment (Fab)

Variable region ofHeavy chain (Vh)

Constant region 1 ofHeavy chain (Ch1)

Future InnovationFuture Innovation

Mouse HumanMouse HumanMouse HumanMouse HumanMouse HumanMouse Human

19


20/23

2010 Trends: Disruptive Technologiesin Medical Devices - Who Could be thenext CoreValve?

Perfusion augmentation therapies


Confidential

20

Patented product to treat specificcardiac artery diseases andavoid open-chest surgery forhundreds of thousands of

patients

Nurturing companiesat the seed stage: MD Start


21/23

2010 Trends: Green ChemistryAlternatives

Biotech alternative to petrochemicalroutes


Confidential

21


22/23

2010 Trends: Pharma Spin-offsEvolution of the Pharma industry (rationalisation concentration)will lead to spin-off opportunities

22


23/23

Breakfast Presentation Jan 26 2010

Documents